You need to enable JavaScript to run this app.
Recon: FDA approves Neurocrine’s add-on Parkinson’s drug; Trial of Sanofi’s Kevzara narrowed to critical COVID-19 patients
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher